Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
One of the drugs Algernon has been investigating is a generic Sanofi neurological drug developed in the 1970’s called Ifenprodil, which is currently approved for use in South Korea and Japan.
Algernon investigated Ifenprodil for IPF, which outperformed the world’s leading two IPF treatments Nintedanib and Pirfenidone, in a pre-clinical in vivo animal study, reducing fibrosis by 56% with statistical significance.
Ifenprodil also outperformed Merck's phase 3 drug Gefapixant in a recent acute cough animal study by 110%.
The Company intends to submit for ethics approval for a phase 2 clinical trial for Ifenprodil for IPF and chronic cough in Australia shortly.
An independent study found that Ifenprodil significantly reduced ALI and improved survivability in an animal study with Avian H5N1 infected mice by 40% (as a result Algernon has decided to expand its Ifenprodil clinical program to include ALI and COVID-19 – read more below). Avian H5N1 is the most lethal form of influenza known to man with an over 50% mortality rate.
Ifenprodil was also shown in a separate independently published in vivo study to prolong survival under anoxic (low oxygen) conditions, as might occur in patients with severely impaired lung function.